NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.

Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic. The company is ready to launch the product this week, so as to make the product available to suffering patients across India.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.896.65 as compared to the previous close of Rs. 890.65. The total number of shares traded during the day was 24495 in over 1143 trades.

The stock hit an intraday high of Rs. 912 and intraday low of 883.55. The net turnover during the day was Rs. 21943996.

Source : Equity Bulls

Keywords